GlucoTrack, Inc. (GCTK)
USD 0.23
(-5.78%)
USD 0.23
(-5.78%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 7.1 Million USD | 60.29% |
| 2022 | 4.43 Million USD | 11.33% |
| 2021 | 3.98 Million USD | 27.11% |
| 2020 | 3.13 Million USD | -15.68% |
| 2019 | 3.71 Million USD | -43.57% |
| 2018 | 6.58 Million USD | -41.05% |
| 2017 | 11.16 Million USD | 78.15% |
| 2016 | 6.26 Million USD | 30.61% |
| 2015 | 4.79 Million USD | 30.85% |
| 2014 | 3.66 Million USD | 21.11% |
| 2013 | 3.02 Million USD | 9.17% |
| 2012 | 2.77 Million USD | 18.86% |
| 2011 | 2.33 Million USD | 67.8% |
| 2010 | 1.39 Million USD | 18.83% |
| 2009 | 1.17 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.48 Million USD | 52.39% |
| 2024 Q1 | 2.94 Million USD | 21.93% |
| 2023 Q1 | 1.28 Million USD | -0.23% |
| 2023 Q4 | 2.41 Million USD | 8.68% |
| 2023 FY | 7.09 Million USD | 60.0% |
| 2023 Q3 | 2.22 Million USD | 88.63% |
| 2023 Q2 | 1.17 Million USD | -8.18% |
| 2022 Q1 | 1.09 Million USD | -24.36% |
| 2022 Q4 | 1.28 Million USD | 38.54% |
| 2022 Q3 | 929 Thousand USD | -17.28% |
| 2022 FY | 4.43 Million USD | 11.33% |
| 2022 Q2 | 1.12 Million USD | 2.74% |
| 2021 FY | 3.98 Million USD | 27.11% |
| 2021 Q2 | 873 Thousand USD | -2.57% |
| 2021 Q3 | 767 Thousand USD | -12.14% |
| 2021 Q4 | 1.44 Million USD | 88.4% |
| 2021 Q1 | 896 Thousand USD | 2.31% |
| 2020 Q4 | 875.72 Thousand USD | -1.31% |
| 2020 Q2 | 611.28 Thousand USD | -19.32% |
| 2020 Q1 | 757.66 Thousand USD | 12.36% |
| 2020 Q3 | 887.32 Thousand USD | 45.16% |
| 2020 FY | 3.13 Million USD | -15.68% |
| 2019 Q4 | 674.3 Thousand USD | -31.52% |
| 2019 Q2 | 1 Million USD | -4.36% |
| 2019 Q3 | 984.64 Thousand USD | -2.01% |
| 2019 Q1 | 1.05 Million USD | 3.81% |
| 2019 FY | 3.71 Million USD | -43.57% |
| 2018 Q3 | 1.61 Million USD | -20.29% |
| 2018 FY | 6.58 Million USD | -41.05% |
| 2018 Q4 | 1.01 Million USD | -37.19% |
| 2018 Q2 | 2.02 Million USD | 4.31% |
| 2018 Q1 | 1.93 Million USD | -38.35% |
| 2017 FY | 11.16 Million USD | 78.15% |
| 2017 Q4 | 3.14 Million USD | 17.76% |
| 2017 Q1 | 2.69 Million USD | 85.77% |
| 2017 Q2 | 2.65 Million USD | -1.45% |
| 2017 Q3 | 2.66 Million USD | 0.47% |
| 2016 Q1 | 1.35 Million USD | -12.95% |
| 2016 Q2 | 1.96 Million USD | 45.19% |
| 2016 FY | 6.26 Million USD | 30.61% |
| 2016 Q4 | 1.45 Million USD | -3.1% |
| 2016 Q3 | 1.49 Million USD | -23.79% |
| 2015 Q1 | 956.52 Thousand USD | -7.99% |
| 2015 Q3 | 1.12 Million USD | -3.44% |
| 2015 Q4 | 1.55 Million USD | 38.41% |
| 2015 Q2 | 1.16 Million USD | 21.64% |
| 2015 FY | 4.79 Million USD | 30.85% |
| 2014 Q4 | 1.03 Million USD | 21.17% |
| 2014 Q3 | 858 Thousand USD | -2.76% |
| 2014 Q2 | 882.32 Thousand USD | -0.55% |
| 2014 Q1 | 887.18 Thousand USD | 13.61% |
| 2014 FY | 3.66 Million USD | 21.11% |
| 2013 Q3 | 727.39 Thousand USD | -12.55% |
| 2013 Q4 | 780.88 Thousand USD | 7.35% |
| 2013 FY | 3.02 Million USD | 9.17% |
| 2013 Q1 | 687.82 Thousand USD | 0.34% |
| 2013 Q2 | 831.79 Thousand USD | 20.93% |
| 2012 Q2 | 754.07 Thousand USD | 16.37% |
| 2012 Q1 | 648 Thousand USD | 8.48% |
| 2012 FY | 2.77 Million USD | 18.86% |
| 2012 Q4 | 685.49 Thousand USD | -0.08% |
| 2012 Q3 | 686.02 Thousand USD | -9.02% |
| 2011 Q2 | 496.72 Thousand USD | -7.86% |
| 2011 Q4 | 597.35 Thousand USD | -14.69% |
| 2011 Q3 | 700.24 Thousand USD | 40.97% |
| 2011 Q1 | 539.12 Thousand USD | 0.0% |
| 2011 FY | 2.33 Million USD | 67.8% |
| 2010 FY | 1.39 Million USD | 18.83% |
| 2009 FY | 1.17 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 104.27 Million USD | 93.187% |
| AngioDynamics, Inc. | 252.41 Million USD | 97.186% |
| AtriCure, Inc. | 327.05 Million USD | 97.828% |
| Avinger, Inc. | 18.63 Million USD | 61.884% |
| Azenta, Inc. | 336.26 Million USD | 97.887% |
| BioLife Solutions, Inc. | 117.57 Million USD | 93.958% |
| The Cooper Companies, Inc. | 1.82 Billion USD | 99.611% |
| Daxor Corporation | 1.28 Million USD | -454.777% |
| Ekso Bionics Holdings, Inc. | 24.19 Million USD | 70.634% |
| Femasys Inc. | 15.2 Million USD | 53.264% |
| Harvard Bioscience, Inc. | 58.58 Million USD | 87.873% |
| Hologic, Inc. | 1.34 Billion USD | 99.472% |
| ICU Medical, Inc. | 717.04 Million USD | 99.009% |
| Intuitive Surgical, Inc. | 2.96 Billion USD | 99.76% |
| KORU Medical Systems, Inc. | 26.1 Million USD | 72.79% |
| LeMaitre Vascular, Inc. | 90.33 Million USD | 92.136% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 6053.289% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 6053.289% |
| Masimo Corporation | 867 Million USD | 99.181% |
| Microbot Medical Inc. | 9.85 Million USD | 27.915% |
| Meihua International Medical Technologies Co., Ltd. | 18.42 Million USD | 61.433% |
| Merit Medical Systems, Inc. | 459.92 Million USD | 98.455% |
| Nephros, Inc. | 9.78 Million USD | 27.392% |
| NovoCure Limited | 613.92 Million USD | 98.843% |
| NEXGEL, Inc. | 4.09 Million USD | -73.438% |
| NEXGEL, Inc. | 4.09 Million USD | -73.438% |
| Singular Genomics Systems, Inc. | 102.24 Million USD | 93.052% |
| OraSure Technologies, Inc. | 125.34 Million USD | 94.332% |
| Pro-Dex, Inc. | 7.37 Million USD | 3.714% |
| Pulse Biosciences, Inc. | 43.57 Million USD | 83.697% |
| Predictive Oncology Inc. | 15.22 Million USD | 53.354% |
| Precision Optics Corporation, Inc. | 8.52 Million USD | 16.64% |
| QuidelOrtho Corporation | 1.35 Billion USD | 99.476% |
| Repligen Corporation | 261.12 Million USD | 97.279% |
| Sanara MedTech Inc. | 61.12 Million USD | 88.378% |
| STAAR Surgical Company | 224.55 Million USD | 96.836% |
| Sharps Technology, Inc. | 10.12 Million USD | 29.848% |
| Utah Medical Products, Inc. | 13.26 Million USD | 46.429% |
| DENTSPLY SIRONA Inc. | 1.79 Billion USD | 99.604% |
| Jin Medical International Ltd. | 3.91 Million USD | -81.337% |